Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Reisman

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Cancer Biology & Therapy|April 10, 2009
Therapeutic targeting of Brahma by HDAC inhibitorsDavid Reisman
Gene|January 15, 2014
The bidirectional p53-Wrap53β promoter is controlled by common cis- and trans-regulatory elementsAmanda Polson, David Reisman
Recent Patents on DNA & Gene Sequences|December 17, 2008
Transcriptional regulation of the p53 tumor suppressor gene: a potential target for cancer therapeutics?David Reisman, Kristy Boggs
Cancer Letters|October 21, 2005
Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-typeShana Thomas, David Reisman
The Journal of Biological Chemistry|January 25, 2007
C/EBPbeta participates in regulating transcription of the p53 gene in response to mitogen stimulationKristy Boggs, David Reisman
Letters in Drug Design & Discovery|April 9, 2013
Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer GeneSarah Gramling, David Reisman
Cell Biochemistry and Function|September 30, 2020
Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressorAnne H Moxley, David Reisman
Apoptosis : an International Journal on Programmed Cell Death|June 29, 2011
Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cyclePaula Takahashi, Amanda Polson, David Reisman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2017
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and ErbituxHarini Bejjanki, Rohit Bishnoi, David Reisman
Cell Biology International|January 13, 2009
RBP-Jkappa binds to and represses transcription of the p53 tumor suppressor geneKristy Boggs, Brystol Henderson, David Reisman
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Cancer Biology & Therapy|April 10, 2009
Therapeutic targeting of Brahma by HDAC inhibitorsDavid Reisman
Gene|January 15, 2014
The bidirectional p53-Wrap53β promoter is controlled by common cis- and trans-regulatory elementsAmanda Polson, David Reisman
Recent Patents on DNA & Gene Sequences|December 17, 2008
Transcriptional regulation of the p53 tumor suppressor gene: a potential target for cancer therapeutics?David Reisman, Kristy Boggs
Cancer Letters|October 21, 2005
Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-typeShana Thomas, David Reisman
The Journal of Biological Chemistry|January 25, 2007
C/EBPbeta participates in regulating transcription of the p53 gene in response to mitogen stimulationKristy Boggs, David Reisman
Letters in Drug Design & Discovery|April 9, 2013
Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer GeneSarah Gramling, David Reisman
Cell Biochemistry and Function|September 30, 2020
Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressorAnne H Moxley, David Reisman
Apoptosis : an International Journal on Programmed Cell Death|June 29, 2011
Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cyclePaula Takahashi, Amanda Polson, David Reisman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2017
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and ErbituxHarini Bejjanki, Rohit Bishnoi, David Reisman
Cell Biology International|January 13, 2009
RBP-Jkappa binds to and represses transcription of the p53 tumor suppressor geneKristy Boggs, Brystol Henderson, David Reisman
Pageof 5